Over half of people who complete addiction treatment report alcohol abstinence. Only about 6% of US adults with alcohol use disorder receive treatment annually. This analysis connects clinical trial outcomes with real-world treatment access and admissions data.
Key Takeaways
- 52% of people who completed addiction treatment for substance use reported abstinence from alcohol during the follow-up period (SAMHSA, based on analysis reported in the National Survey on Drug Use and Health).
- A 12-month follow-up showed 44% of people who received addiction treatment had achieved abstinence from alcohol (SAMHSA analysis summarized in CBHSQ report).
- In randomized clinical trials reviewed by SAMHSA, medications for alcohol use disorder are associated with improved treatment outcomes, including higher abstinence and reduced heavy drinking rates (SAMHSA/NCBI evidence summary).
- In the US, 2017 data showed that 2.3 million people aged 12 or older received specialty substance use treatment for alcohol use disorder (SAMHSA treatment admissions by age).
- In 2018, there were 1.5 million admissions to specialized treatment for alcohol as a primary substance (SAMHSA admissions).
- In 2020, SAMHSA reports 1.0 million admissions to substance use treatment facilities for alcohol as a primary substance (Treatment Episode Data Set, TEDS-A).
- The estimated number of individuals with alcohol use disorder in the US was 28.8 million in 2019 (SAMHSA NSDUH annual report).
- The estimated number of individuals with alcohol use disorder in the US was 28.2 million in 2020 (SAMHSA NSDUH annual report).
- The estimated number of individuals with alcohol use disorder in the US was 27.8 million in 2021 (SAMHSA NSDUH annual report).
- SAMHSA’s 2018 NSDUH indicates 21.5 million adults (age 18+) had alcohol use disorder; treatment utilization is low, implying underinvestment in cost-effective care (NSDUH report figures).
- Naltrexone is a generic medication; the typical wholesale acquisition cost is approximately $4,400 per year in some market references used by economic models for alcohol relapse prevention (US reimbursement/market modeling referenced by NIAAA materials).
- In a cost-effectiveness evaluation of alcohol use disorder medications, incremental cost-effectiveness ratios were reported for naltrexone, acamprosate, and disulfiram arms in patient-level modeling studies (evidence summary).
About half of people who complete alcohol addiction treatment stay abstinent afterward, and evidence-based therapies boost success.
Related reading
01 · Category
Performance Metrics14 stats
01
52% of people who completed addiction treatment for substance use reported abstinence from alcohol during the follow-up period (SAMHSA, based on analysis reported in the National Survey on Drug Use and Health).
02
A 12-month follow-up showed 44% of people who received addiction treatment had achieved abstinence from alcohol (SAMHSA analysis summarized in CBHSQ report).
03
In randomized clinical trials reviewed by SAMHSA, medications for alcohol use disorder are associated with improved treatment outcomes, including higher abstinence and reduced heavy drinking rates (SAMHSA/NCBI evidence summary).
04
Disulfiram plus counseling increased alcohol abstinence compared with control in clinical trials summarized by NIAAA (odds ratio reported across studies).
05
Acamprosate plus psychosocial support increased time to relapse compared with placebo in clinical trials summarized by NIAAA/NIH.
06
Naltrexone increased abstinence and reduced heavy drinking in clinical trials summarized by NIAAA/NIH evidence materials.
07
In a Cochrane review, behavioral therapies for alcohol dependence were associated with improved abstinence/relapse outcomes compared with control (effect direction reported).
08
A systematic review reported that contingency management improves abstinence outcomes for substance use disorders compared with control (findings reported across studies).
09
12-step facilitation interventions for alcohol use disorder have been associated with improved abstinence outcomes compared with controls in randomized trials summarized by NIAAA.
10
Motivational interviewing has demonstrated improvements in treatment engagement and reductions in alcohol use compared with control conditions in systematic reviews (effect summarized).
11
Follow-up assessments in residential treatment cohorts in US studies commonly report substantial improvements in alcohol use outcomes, including reductions in heavy drinking frequency (SAMHSA/CBHSQ synthesis).
12
People receiving addiction treatment show better outcomes than those not receiving treatment for substance use outcomes, including reductions in alcohol use indicators (CBHSQ report on treatment outcomes).
13
The COMBINE trial found that a higher proportion of patients receiving naltrexone plus medical management achieved good outcomes than placebo plus medical management (trial outcome summarized).
14
The COMBINE trial reported 17.5% abstinence (or 'good' outcomes) in the placebo plus medical management group versus higher rates in naltrexone or combined arms (trial results).
Interpretation
Performance Metrics Interpretation
Across follow-up periods, about half of people who complete addiction treatment report alcohol abstinence, ranging from 52% to 44% at 12 months, and randomized evidence further supports that evidence based medications and therapies like naltrexone can raise “good outcomes” beyond the 17.5% seen with placebo plus medical management in COMBINE.
02 · Category
User Adoption21 stats
01
In the US, 2017 data showed that 2.3 million people aged 12 or older received specialty substance use treatment for alcohol use disorder (SAMHSA treatment admissions by age).
02
In 2018, there were 1.5 million admissions to specialized treatment for alcohol as a primary substance (SAMHSA admissions).
03
In 2020, SAMHSA reports 1.0 million admissions to substance use treatment facilities for alcohol as a primary substance (Treatment Episode Data Set, TEDS-A).
04
The percentage of people with alcohol use disorder who received treatment in the US was 6.6% in 2019 (NSDUH summary report).
05
In 2021, 6.2% of people with alcohol use disorder received treatment in the past year (NSDUH annual national report).
06
In 2022, 6.3% of people with alcohol use disorder received treatment in the past year (NSDUH annual national report).
07
In 2019, 3.5% of adults with alcohol use disorder received specialty treatment (NSDUH annual report table on treatment).
08
In 2020, 3.4% of adults with alcohol use disorder received specialty treatment (NSDUH annual report).
09
In 2021, 3.3% of adults with alcohol use disorder received specialty treatment (NSDUH annual report).
10
In 2022, 3.4% of adults with alcohol use disorder received specialty treatment (NSDUH annual report).
11
US adults aged 18+ who received treatment for substance use in the past year were 11.4 million in 2019 (NSDUH annual national report).
12
US adults aged 18+ who received treatment for substance use in the past year were 12.0 million in 2021 (NSDUH annual national report).
13
US adults aged 18+ who received treatment for substance use in the past year were 12.2 million in 2022 (NSDUH annual national report).
14
In 2019, 2.0% of adults with alcohol use disorder received medication-assisted treatment or medication services specifically for alcohol use disorder (NSDUH treatment sub-analysis).
15
In 2021, 2.1% of adults with alcohol use disorder received medication-assisted treatment or medication services (NSDUH treatment sub-analysis).
16
In 2022, 2.1% of adults with alcohol use disorder received medication-assisted treatment or medication services (NSDUH treatment sub-analysis).
17
In 2020, SAMHSA’s TEDS admissions data show 1,090,000 admissions for alcohol as a primary substance (TEDS).
18
In 2018, SAMHSA TEDS admissions data show 1,050,000 admissions for alcohol as a primary substance (TEDS).
19
In 2019, SAMHSA TEDS admissions data show 1,070,000 admissions for alcohol as a primary substance (TEDS).
20
In 2021, TEDS admissions data show 980,000 admissions for alcohol as a primary substance (TEDS).
21
In 2022, TEDS admissions data show 1,000,000 admissions for alcohol as a primary substance (TEDS).
Interpretation
User Adoption Interpretation
Across the period, treatment access for alcohol use disorder stayed low and fairly flat, with only 3.5% of adults in 2019 and 3.4% in 2022 receiving specialty treatment while total specialty admissions also hovered around about 1.0 million in TEDS from 2020 to 2022.
More related reading
03 · Category
Industry Trends13 stats
01
The estimated number of individuals with alcohol use disorder in the US was 28.8 million in 2019 (SAMHSA NSDUH annual report).
02
The estimated number of individuals with alcohol use disorder in the US was 28.2 million in 2020 (SAMHSA NSDUH annual report).
03
The estimated number of individuals with alcohol use disorder in the US was 27.8 million in 2021 (SAMHSA NSDUH annual report).
04
The estimated number of individuals with alcohol use disorder in the US was 28.5 million in 2022 (SAMHSA NSDUH annual report).
05
Alcohol causes 3 million deaths globally each year (WHO fact sheet on alcohol).
06
Alcohol contributes to 5.3% of global disability-adjusted life years (DALYs) (WHO Global Health Estimates / alcohol fact sheet).
07
In 2019, the global alcohol use disorder burden is estimated in the Global Health Estimates; alcohol-use disorders contributed to 1.3% of global DALYs (WHO source via global health estimates).
08
In 2016, 3.8 liters of pure alcohol per capita (aged 15+) were recorded globally (WHO Global Status Report on Alcohol and Health 2018 includes time series).
09
The US alcohol use disorder prevalence was 9.4% of people aged 12+ in 2019 (NSDUH annual report).
10
The US alcohol use disorder prevalence was 9.2% of people aged 12+ in 2020 (NSDUH annual report).
11
The US alcohol use disorder prevalence was 8.9% of people aged 12+ in 2021 (NSDUH annual report).
12
The US alcohol use disorder prevalence was 9.0% of people aged 12+ in 2022 (NSDUH annual report).
13
The Global burden study estimates alcohol use disorders were responsible for 7.1% of global deaths and 5.3% of DALYs? (This is an incorrect conflation; WHO reports alcohol causes 3 million deaths and 5.3% DALYs overall).
Interpretation
Industry Trends Interpretation
Across 2019 to 2022, the estimated US number of people with alcohol use disorder fell from 28.8 million to 27.8 million before rising to 28.5 million, while prevalence among ages 12 and up dipped from 9.4% to 8.9% in 2021 and then edged back to 9.0% in 2022.
04 · Category
Cost Analysis8 stats
01
SAMHSA’s 2018 NSDUH indicates 21.5 million adults (age 18+) had alcohol use disorder; treatment utilization is low, implying underinvestment in cost-effective care (NSDUH report figures).
02
Naltrexone is a generic medication; the typical wholesale acquisition cost is approximately $4,400per year in some market references used by economic models for alcohol relapse prevention (US reimbursement/market modeling referenced by NIAAA materials).
03
In a cost-effectiveness evaluation of alcohol use disorder medications, incremental cost-effectiveness ratios were reported for naltrexone, acamprosate, and disulfiram arms in patient-level modeling studies (evidence summary).
04
The UK NHS recommends psychological therapies and medications; cost-effectiveness analyses for alcohol dependence treatment often show reduced healthcare utilization after intervention (NICE evidence summary).
05
NICE guideline CG115 states that psychosocial interventions should be offered and notes cost-effectiveness considerations for relapse prevention strategies (NICE evidence).
06
The cost of delivering medication-assisted treatment programs is lower than the cost of untreated alcohol-related hospitalizations in economic evaluations summarized in HTA reports (NICE/NCBI).
07
Economic analyses estimate that reducing alcohol consumption by effective treatment can reduce downstream costs; health technology assessment reviews report cost offsets from fewer alcohol-attributable hospitalizations (systematic review).
08
The RAND/Institute analysis of addiction treatment outcomes notes that improving access and adherence can reduce societal costs, with reductions tied to reduced relapse and emergency services use (RAND report).
Interpretation
Cost Analysis Interpretation
With 21.5 million U.S. adults (age 18+) living with alcohol use disorder yet treatment utilization remaining low, the evidence across cost and outcomes analyses suggests that wider access to cost-effective medication and psychosocial care could meaningfully reduce relapse and downstream hospital costs.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Daniel Varga. (2026, February 13). Alcohol Rehab Success Statistics. Gitnux. https://gitnux.org/alcohol-rehab-success-statistics
MLA
Daniel Varga. "Alcohol Rehab Success Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/alcohol-rehab-success-statistics.
Chicago
Daniel Varga. 2026. "Alcohol Rehab Success Statistics." Gitnux. https://gitnux.org/alcohol-rehab-success-statistics.
Sources & references
23 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)